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Abstract
Post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) ≥0.90
confers an improved cardiac prognosis. There are currently limited data available to
determine how often it is possible to improve an angiographically acceptable but
physiologically suboptimal result. A physiology-guided optimization strategy can
achieve a clinically meaningful increase in the proportion of patients achieving a final
post-PCI FFR ≥0.90 compared to standard care. Following angiographically successful
PCI procedures, 260 patients will be randomized (1:1) to receive either a physiology-
guided incremental optimization strategy (intervention group) or blinded post-PCI
coronary physiology measurements (control group). Patients undergoing successful,
standard-of-care PCI for either stable angina or non-ST-segment-elevation myocar-
dial infarction who meet the study's inclusion and exclusion criteria will be eligible for
randomization. The primary endpoint is defined as the proportion of patients with a
final post-PCI FFR result ≥0.90. Secondary endpoints include change from baseline in
Seattle Angina Questionnaire and EQ-5D-5L scores at 3 months and the rate of tar-
get vessel failure and its components (cardiac death, myocardial infarction, stent
thrombosis, unplanned rehospitalization with target vessel revascularization) at
3 months and 1 year. 260 individual patients were successfully randomized between
March 2018 and November 2019. Key baseline demographics of the study popula-
tion are reported within. TARGET FFR is an investigator-initiated, prospective, single-
center, randomized controlled trial of an FFR-guided PCI optimization strategy. The
study has completed recruitment and is now in clinical follow-up. It is anticipated that
primary results will be presented in Autumn 2020.
Abbreviations: CFR, coronary flow reserve; dPR, diastolic pressure ratio; FFR, fractional flow reserve; HTG, hyperemic tran-stent gradient; IC, intracoronary; iFR, instantaneous wave-free ratio;
IMR, index of microcirculatory resistance; ISR, in-stent restenosis; IVUS, intravascular ultrasound; MACE, major adverse cardiovascular events; NSTEMI, non-ST segment elevation myocardial
infarction; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; Pd/Pa, distal coronary pressure/aortic pressure; PIOS, physiologically guided incremental optimization
strategy; RFR, resting full-cycle ratio; SAQ, Seattle Angina Questionnaire; STEMI, ST-segment elevation myocardial infarction; TThyp, mean hyperemic transit time; TTrest, mean resting
transit time.
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1 | INTRODUCTION
The utility of fractional flow reserve (FFR) for assessing the physio-
logical significance of coronary stenoses and the benefits of FFR-
guided decision making prior to percutaneous coronary interven-
tion (PCI) have been well-established in randomized clinical trials.1,2
However, FFR is rarely used to assess the final PCI result where
standard practice continues to be angiographic assessment alone.
From a registry of 750 patients receiving bare metal stents, Pijls
et al reported that at 6-month follow-up, the lowest event rates
occurred in patients with post-PCI FFR ≥0.90.3 Studies and related
meta-analyses involving drug-eluting stents have suggested similar
cutoff values of post-PCI FFR to predict improved clinical out-
comes.4-12 These range from 0.89 to ≥0.92 with a large systematic
review and meta-analysis of 7470 patients concluding that a post-
PCI FFR ≥0.90 was associated with a significantly lower risk of
repeat PCI and major adverse cardiovascular events.10 Johnson
et al correlated the immediate post-PCI FFR results from
966 patients with clinical outcomes out to 3 years and demon-
strated a significant, inverse relationship between post-PCI FFR
and subsequent clinical events.13
Published values for overall mean or median final post-PCI FFR
results range from 0.84 to 0.95.3,5-7,9,12,14-37 The proportion of
patients actually achieving a final FFR ≥0.90 varies widely between
studies and ranges from 37% to 93%.3-8,16,18,29,38,39 Of perhaps
greater concern however, is the incidence of suboptimal FFR results
after stenting. Where reported, the proportion of patients with post-
PCI FFR values ≤0.80 ranges from 4% to 20%.9,11,24,28,34,37,40 This
indicates that, despite angiographically satisfactory results, as many as
one in five patients may have a post-PCI FFR result that remains
below the threshold for performing revascularization in the first place.
With up to 38% of patients still reporting angina 1 year after PCI
procedures,41 it seems plausible that persistently abnormal post-PCI
FFR results may be associated with symptom recurrence.
It has been suggested that non-hyperemic pressure ratios
(NHPRs), such as the instantaneous wave-free ratio (iFR), also have
potential to be used as objective measures of improvement in physiol-
ogy following PCI.25 A recent study employing blinded post-PCI iFR
assessments reported residual ischemia (iFR <0.90) in nearly one in
four patients despite angiographically successful stenting results. The
authors concluded that 81.6% of these cases were due to inapparent
focal lesions potentially amenable to treatment with additional PCI.42
While an NHPR-guided PCI optimization strategy might be more
appealing to clinicians as it could facilitate multiple physiological
assessments without the need to repeatedly induce hyperemia, data
on the prognostic value of post-PCI NHPR values are currently lac-
king. The original NHPR, the ratio of distal coronary to aortic pressure
(Pd/Pa) is routinely available with all diagnostic guidewires. Recently,
two new resting physiology indices have been developed which have
diagnostic equivalence to iFR: the diastolic pressure ratio (dPR) and
the resting full-cycle ratio (RFR).43,44
One of the reasons clinicians do not routinely measure post-PCI
FFR is that there are currently limited data available to determine how
often it is possible to improve an angiographically acceptable but
physiologically suboptimal result.
Given the potential prognostic significance of post-PCI FFR, but
general lack of adoption, there is a clear need for randomized con-
trolled trials to:
1. establish the prevalence of suboptimal post-PCI FFR results in clin-
ical practice;
2. systematically categorize the remediable mechanisms where this
occurs;
3. establish which PCI optimization strategies can effectively increase
the proportion of patients with functionally optimal
revascularization.
2 | METHODS
TARGET FFR is an investigator-initiated, prospective, single-center,
randomized controlled trial of an FFR-guided PCI optimization strat-
egy. The primary hypothesis is that this strategy will result in a clini-
cally meaningful increase in the proportion of patients achieving a
final post-PCI FFR ≥0.90 compared to standard care. Following angio-
graphically successful PCI procedures, 260 patients will be random-
ized (1:1) to receive either a physiology-guided incremental
optimization strategy (PIOS intervention group) or blinded post-PCI
coronary physiology measurements (control group). Patients undergo-
ing successful, standard-of-care PCI for either stable angina or Non-
ST segment elevation myocardial infarction (NSTEMI) who meet the
study's inclusion and exclusion criteria (Table 1) will be eligible for ran-
domization. All patients will complete the Seattle Angina Question-
naire (SAQ-7) and EQ-5D-5L questionnaire both prior to, and
3 months after, their procedure. Longer term outcomes will be
assessed using record linkage. The study flowchart is depicted in
Figure 1.
2.1 | Study endpoints
The primary endpoint is defined as the proportion of patients with a
final post-PCI FFR result ≥0.90.
Secondary endpoints include:
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1. the proportion of patients with FFR ≤0.80;
2. the change from baseline in SAQ-7 at 3 months;
3. the change from baseline in EQ-5D-5L scores at 3 months;
4. the rate of target vessel failure (TVF) and its components (cardiac
death, myocardial infarction, stent thrombosis, unplanned
rehospitalization with target vessel revascularization) at 3 months
and 1 year.
A complete list of secondary outcome measures is provided in
Table 2.
2.2 | Study procedures
PCI procedures will be performed according to standard clinical prac-
tice. Treatment decisions (including the use of adjunctive
intracoronary imaging such as OCT or IVUS) and the definition of an
angiographically acceptable PCI result will be left entirely to the oper-
ator's judgment. The study protocol mandates that all enrolled
patients should have pre-PCI coronary physiology assessments per-
formed, however, the decision whether to then use the pressure wire
for PCI or employ an alternative angioplasty wire is at the operator's
discretion. Decisions on choice and duration of antiplatelet medica-
tions and/or combination with anticoagulant therapy will also be left
to the operator's clinical judgment. Patients will only be randomized
and post-PCI study measurements/interventions performed after the
operator has declared the standard care procedure to be complete.
2.3 | PIOS intervention group (group A)
If post-PCI FFR is <0.90, the coronary physiology results and hyper-
emic pullback assessment will be disclosed to the operator. Based on
the interpretation of the pullback recording, the operator will attempt
to obtain the target optimal post-PCI FFR result by following the steps
of the PIOS algorithm outlined below:
TABLE 1 Inclusion/exclusion criteria
Inclusion criteria
• Patients >18 years of age with coronary artery disease including
stable angina and NSTEMI
• Participants must be able to provide informed consent
Exclusion criteria
• PCI in a coronary artery bypass graft
• PCI to an ISR lesion
• PCI to a target artery providing Rentrop grade 2 or 3 collateral
blood supply to another vessel
• Inability to receive adenosine (eg, severe reactive airway
disease, marked hypotension, or advanced atrioventricular block
without pacemaker).
• Recent (within 1 week prior to cardiac catheterisation) STEMI in
any arterial distribution (not specifically target lesion).
• Severe cardiomyopathy (LVEF <30%).
• Renal insufficiency such that an additional 20 to 30 mL of
contrast would, in the opinion of the operator, pose
unwarranted risk to the patient.
Abbreviations: ISR, in-stent restenosis; LVEF—left ventricular ejection
fraction; NSTEMI, non-ST segment myocardial infarction; PCI,
percutaneous coronary intervention; STEMI—ST-segment elevation
myocardial infarction.
F IGURE 1 Target FFR study
flowchart. PIOS—physiologically
guided incremental optimization
strategy
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1. If the residual pressure gradient is interpreted to reflect diffuse
atherosclerosis with no focal step-ups, the result is accepted and
no optimization is attempted.
2. If there is a hyperemic trans-stent gradient (HTG) ≥0.05 further
postdilation with a larger non-compliant balloon to at least
18 atm should be performed followed by repeat FFR. Addition-
ally, the operator may choose to employ intracoronary imaging
(IVUS or OCT) to guide postdilation/optimization of the stented
segment.
3. If there is a step-up of ≥0.05 across a relatively focal (<20 mm)
unstented segment that is technically suitable for further stenting,
then a further stent should be deployed followed by repeat FFR.
4. If the FFR remains <0.90 after steps B ± C, a further FFR pullback
will be performed. If the criteria for further stent optimization or
implantation are again met, additional postdilation should be
undertaken and/or one additional stent may be deployed followed
by a final FFR pullback.
2.4 | Control group (group B)
In keeping with standard care, the operator will determine proce-
dural completeness and success based on the angiographic and/or
intracoronary imaging appearances. Post-PCI coronary physiology
measurements will be performed but not disclosed to the operator.
No further intervention or optimization measures will be
undertaken.
2.5 | Follow-up
Follow-up will be performed by clinical research nurses blinded to
both the assigned treatment arm and the final FFR result. All patients
will be contacted by letter and/or telephone 3 months after their PCI
procedure to repeat the SAQ-7 and EQ-5D-5L questionnaires. In
cases where an adverse event or clinical endpoint has occurred, addi-
tional information will be retrieved from the patient's electronic health
record or general practitioner. Clinical outcomes will be reviewed
again at 1 year using electronic health record linkage.
2.6 | Pilot data, power, and sample size calculation
Pilot data from 50 patients who underwent post-PCI FFR assessment
at our institution revealed that an initial post-PCI FFR result ≥0.90
was achieved in only 16/50 (32%). Additional optimization measures
(further postdilation, stenting or both) were attempted in just nine
patients (18%). Initial post-PCI FFR increased from a median of 0.83
(0.80-0.86) to a final FFR of 0.88 (0.86-0.89) in these patients. The
results of pullback measurements performed in all 50 vessels, how-
ever, revealed at least one target for additional optimization measures
was present in up to 40% of patients (HTG ≥0.05 in 19/50 (38%);
focal step-up ≥0.05 either proximal or distal to the stented segment in
21/50 (42%). It is hypothesized that systematically applying the PIOS
intervention will result in a 20% absolute increase in the proportion of
patients with a final post-PCI FFR ≥0.90 compared to the control
group. A sample size of 130 patients per group would be required to
have 90% power to detect a 20% difference between groups at the
5% significance level; therefore, 260 patients will be randomized.
Patients presenting with stable angina or NSTEMI who attend our
institution for diagnostic coronary angiography proceed to PCI during
the same procedure in approximately 40% of cases. It is therefore
estimated that approximately 650 patients will be enrolled in the
study in order to randomize 260 patients following their standard-of-
care PCI.
TABLE 2 Secondary outcome measures of the target FFR study
Patient-reported outcome measures
• Change from baseline in SAQ and EQ-5D-5L scores at 3 months
3-month and 1-year follow-up
• The rate of TVF and its components (cardiac death, myocardial
infarction, stent thrombosis, unplanned rehospitalization with
target vessel revascularization)
Additional coronary physiology outcomes
• The proportion of patients with final post-PCI FFR ≤0.80
• The proportion of patients with final post-PCI dPR ≥0.90
• The proportion of patients with final post-PCI RFR ≥0.90
• The proportion of patients with final post-PCI CFR ≥2.0
• The proportion of patients with final post-PCI IMR >25
• The proportion of patients with final post-PCI IMRc >25
• ΔFFR from pre-PCI to final post-PCI value
• ΔdPR from pre-PCI to final post-PCI value
• ΔRFR from pre-PCI to final post-PCI value
• ΔCFR from pre-PCI to final post-PCI value
• Δ TTrest from pre-PCI to final post-PCI value
• Δ TThyp from pre-PCI to final post-PCI value
• ΔIMR from pre-PCI to final post-PCI value
• ΔIMRc from pre-PCI to final post-PCI value
• ΔFFR from pre-PCI to final post-PCI value
• Percent FFR change from pre-PCI to final post-PCI value
• Percent dPR change from pre-PCI to final post-PCI value
• Percent RFR change from pre-PCI to final post-PCI value
• Percent CFR change from pre-PCI to final post-PCI value
• Percent TTrest change from pre-PCI to final post-PCI value
• Percent TThyp change from pre-PCI to final post-PCI value
• Percent IMR change from pre-PCI to final post-PCI value
• Percent IMRc change from pre-PCI to final post-PCI value
Procedural characteristics
• Procedure duration
• Cost of additional equipment employed in the experimental arm
• Fluoroscopy dose
• Contrast material dose
• Incidence of procedural complications such as coronary artery
dissection or perforation.
• Incidence of significant pressure wire drift (≥ ±0.04)
Additional analyses
• An “as-treated” analysis of the primary and preceding secondary
outcome measures
Abbreviations: CFR, coronary flow reserve; dPR, diastolic pressure ratio;
FFR, fractional flow reserve; IMR, index of microcirculatory resistance;
IMRc, corrected index of microcirculatory resistance; RFR, resting full-
cycle ratio; SAQ, Seattle Angina Questionnaire; TThyp, mean hyperemic
transit time; TTrest, mean resting transit time; TVF, target vessel failure.
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TABLE 3 Baseline patient demographics (preliminary results)
Total (n = 260) PIOS (n = 131) Control (n = 129)
Male 226 (86.9%) 117 (89.3%) 109 (84.5%)
Age 59 (54-66) 58 (54-66) 60 (55-68)
BMI 29 (27-32) 29 (26-32) 29 (27-32)
Hypertension 116 (44.6%) 58 (44.3%) 58 (45%)
Hypercholesterolemia 146 (56.2%) 72 (55%) 74 (57.4%)
Diabetes 49 (18.8%) 24 (18.3%) 25 (19.4%)
OHAs 42 (85.7%) 21 (87.5%) 21 (84%)
Insulin 5 (10.2%) 3 (12.5%) 2 (8%)
Atrial fibrillation 19 (7.3%) 10 (7.6%) 9 (7%)
OAC 13 (68.4%) 6 (60%) 7 (77.8%)
CHA2DS2-Vasc
2 6 (31.6%) 3 (15.8%) 3 (15.8%)
3 4 (21.1%) 3 (30%) 1 (11.1%)
4 4 (21.1%) 2 (20%) 2 (22.2%)
5 4 (21.1%) 2 (20%) 2 (22.2%)
6 1 (5.3%) 0 1 (11.1%)
Previous TIA/stroke 17 (6.5%) 8 (6.1%) 9 (7%)
CKDa 5 (1.9%) 3 (2.3%) 2 (1.6%)
Family history of CAD 172 (66.2%) 88 (67.2%) 84 (65.1%)
History of smoking 183 (70.4%) 92 (70.2%) 91 (70.5%)
Current 50 (27.3%) 28 (30.4%) 22 (24.2%)
Within past year 41 (22.4%) 22 (23.9%) 19 (20.9%)
Ex-smoker >1 y 92 (50.3%) 42 (45.7%) 50 (54.9%)
Thyroid dysfunction 20 (7.7%) 9 (6.9%) 11 (8.5%)
Heart failure 44 (16.9%) 28 (21.4%) 16 (12.4%)
NYHA class 1 29 (65.9%) 19 (67.9%) 10 (62.5%)
NYHA class 2 15 (34.1%) 9 (32.1%) 6 (37.5%)
HFrEF 43 (97.7%) 28 (100%) 15 (93.8%)
Previous MI 95 (36.5%) 50 (38.2%) 45 (34.9%)
Previous PCI 100 (38.5%) 54 (41.2%) 46 (35.7%)
Previous CABG 1 (0.4%) 1 (0.8%) 0
Valvular heart disease 8 (3.1%) 2 (1.5%) 6 (4.7%)
Aortic stenosis 6 (2.3%) 1 (0.8%) 5 (3.9%)
Mitral regurgitation 2 (0.8%) 1 (0.8%) 1 (0.8%)
Angina 215 (82.7%) 107 (81.7%) 108 (83.7%)
CCS class 1 58 (27%) 28 (26.2%) 30 (27.8%)
CCS class 2 101 (47%) 51 (47.7%) 50 (46.3%)
CCS class 3 55 (25.6%) 27 (25.2%) 28 (25.9%)
CCS class 4 1 (0.5%) 1 (0.9%) 0
Cardiac medications
Single APT 253 (97.3%) 128 (97.7%) 125 (96.9%)
Dual APT 185 (71.2%) 97 (74.1%) 88 (68.2%)
OAC 16 (6.2%) 8 (6.1%) 8 (6.2%)
Statin 250 (96.2%) 127 (97%) 123 (95.4%)
Beta blocker 237 (91.2%) 121 (92.4%) 116 (89.9%)
CCB 52 (20%) 22 (16.8%) 30 (23.3%)
(Continues)
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2.7 | Statistical analysis
The study data will be summarized for the randomized population
overall, and by randomized group. The number of observations and
number of missing values will be reported. Continuous variables
will have normality tests applied and be summarized using the
mean ± SD or median and interquartile range according to their
distribution. Differences in continuous variables between random-
ized groups will be assessed using Student's t tests or Mann-
Whitney U tests as appropriate. The Pearson correlation coeffi-
cient will be applied to parametric variables while correlation
between nonparametric variables will be assessed using Spe-
arman's rank correlation. Categorical variables will be summarized
with frequencies and percentages. Differences in categorical
TABLE 3 (Continued)
Total (n = 260) PIOS (n = 131) Control (n = 129)
ACEI 175 (67.3%) 91 (69.5%) 84 (65.1%)
ARB 23 (8.9%) 11 (8.4%) 12 (9.3%)
Diuretic 30 (11.5%) 13 (9.9%) 17 (13.2%)
GTN spray 123 (47.3%) 61(46.6%) 62 (48.1%)
Used daily 30 (24.4%) 13 (21.3%) 17 (27.4%)
Used weekly 67 (54.55) 34 (55.7%) 32 (51.6%)
Used monthly 27 (22%) 14 (23%) 13 (21%)
Oral nitrate 69 (26.5%) 26 (19.9%) 43 (33.3%)
Nicorandil 22 (8.5%) 14 (10.7%) 8 (6.2%)
Ivabradine 5 (1.9%) 3 (2.3%) 2 (1.6%)
No. anti-anginal meds
0 9 (3.5%) 4 (3.1%) 5 (3.9%)
1 99 (38.1%) 55 (42%) 44 (34.1%)
2 114 (43.8%) 55 (42%) 59 (45.7%)
3 31 (11.9%) 13 (9.9%) 18 (14%)
4 7 (2.7%) 4 (3.1%) 3 (2.3%)
Indication
Stable angina 88 (33.9%) 40 (30.5%) 48 (37.2%)
Staged PCI 16 (18.2%) 8 (20%) 8 (16.7%)
ACS-NSTEMI 101 (38.8%) 50 (38.2%) 51 (39.5%)
Days post-MI 21 (12-28.5) 20 (7-26.3) 23 (16-31)
ACS-unstable angina 3 (1.2%) 2 (1.5%) 1 (0.8%)
Staged PCI/completion of revascularization 68 (26.2%) 39 (29.8%) 29 (22.5%)
Post-STEMI 46 (67.7%) 29 (74.4%) 17 (58.6%)
Days since MI 68.8±29.5 70.4±30.9 66.1±27.6
Post-NSTEMI 22 (32.4%) 10 (25.6%) 12 (41.4%)
Days since MI 67 (54-98) 64 (54-86.8) 79.5 (53.3-110.8)
Target vessel
LAD 149 (57.3%) 75 (57.3%) 74 (57.4%)
RCA 67 (25.8%) 28 (21.4%) 39 (30.2%)
LCx 33 (12.7%) 20 (15.3%) 13 (10.1%)
OM 10 (3.8%) 8 (6%) 2 (1.6%)
Diagonal 1 (0.4%) 0 1 (0.8%)
aAll five patients had stage 3a CKD (eGFR 45-59): mild-moderate renal impairment.
Abbreviations: ACEI, angiotensin converting enzyme inhibitor; ACS, acute coronary syndrome; APT, antiplatelet therapy; ARB, angiotensin II-receptor
blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCB, calcium channel blocker; CCS, Canadian
cardiovascular society; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; GTN, glyceryl trinitrate; HFrEF, heart failure with reduced
ejection fraction; LAD, left anterior descending; LCx, left circumflex; MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction;
OAC, oral anticoagulant; OHAs, oral hypoglycemic agents; OM, obtuse marginal; PCI, percutaneous coronary intervention; RCA, right coronary artery;
STEMI, ST-segment elevation myocardial infarction.
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variables between randomized groups will be evaluated using Chi-
square tests or Fisher's exact tests.
Where relevant, changes from baseline will be summarized. Multivar-
iate logistic regression analyses will be employed to assess for clinical pre-
dictors of post-PCI FFR values ≥0.90 and ≤0.80. The primary outcome
will be summarized in the full analysis set as a whole and by treatment
group. A test and 95% CI for two proportions (adjustedWald method) will
be employed, together with Fisher's exact test. Additional secondary ana-
lyses on this outcome will use logistic regression to investigate whether
any of the baseline characteristics affect the outcome. This will be per-
formed by first investigating each characteristic on its own (together with
the treatment group). Any variables that are significant here will be added
to build a larger model, bearing in mind sample size limitations. For the
binary categorical secondary outcomes, the same analysis approach will
be used as with the primary outcome. For quantitative secondary out-
comes, two sample t tests or Mann Whitney U tests will be used as
appropriate, as well as further analyses using regression to investigate
whether any of the baseline characteristics affect the outcome. All tests
will be two sided and a P-value of <.05 will be considered significant. Effi-
cacy analyses will be carried out according to the intention to treat princi-
ple, that is, in relation to randomized treatment allocation, rather than
treatment received. Safety analyses will be carried out in relation to treat-
ment received. Details of subgroup and additional analyses are provided
in the Supplementary Appendix.
2.8 | Study organization
The study received ethical approval from the West of Scotland
Research Ethics Service (17/WS/0153) and will be conducted in accor-
dance with the International Conference on Harmonization Good Clini-
cal Practice (ICH GCP) Guideline and the Declaration of Helsinki (64th
World Medical Association General Assembly, Fortaleza, Brazil,
October 2013). The study sponsor is the NHS National Waiting Times
Centre Board (Golden Jubilee National Hospital). Details of the Trial
Steering Committee, Clinical Endpoints Committee, and Physiology
Core Lab are provided in the Supplementary Appendix.
3 | RESULTS
Between March 8, 2018 and November 22, 2019, we successfully
randomized 260 patients meeting the trial's inclusion and exclusion
criteria. Preliminary baseline characteristics of the study population
are presented in Table 3. The trial is now in clinical follow-up and it is
anticipated the primary results will be presented in Autumn 2020.
4 | DISCUSSION
Prior studies of post-PCI FFR have recruited patients with either sta-
ble angina or recent NSTEMI. However, while in general enrolling het-
erogeneous populations enhances external validity, in this case, the
performance of the diagnostic test may differ according to the nature
of the coronary artery disease. By measuring CFR and IMR with FFR
we aim to take account of microvascular dysfunction to help inform
the interpretation of the primary and secondary physiology outcomes.
The sample size calculation is based on pilot data which identified
potential targets for additional intervention following an index PCI
procedure. The indication for the PIOS intervention may be more lim-
ited if a high proportion of patients have a post-PCI FFR ≥0.90 or if
there is a higher incidence of the diffuse gradient disease pattern in
the population than predicted. This could result in the study being
underpowered. Currently, there are limited data on the potential to
further optimize the physiological result of a PCI procedure. Agarwal
et al reported that 137 of the 664 lesions (20.6%) in their patient
cohort underwent additional PCI based on the presence of a persis-
tently ischemic, or if not ischemic, “unsatisfactory” (as determined by
the operator) initial post-PCI FFR.7 The mean initial FFR for these
lesions was 0.78 ± 0.07. 58/137 lesions (42%) received further
postdilation of the implanted stent with a bigger balloon size and
higher pressure and duration of inflation. 45/137 (33%) had another
stent implanted while 24/137 (18%) underwent both additional ste-
nting and balloon postdilation. These subsequent interventions led to
an improvement in FFR in this subgroup from 0.78 ± 0.07 to 0.87
± 0.05. Overall, suboptimal initial post-PCI FFR prompting subsequent
intervention led to an increase in lesions with final FFR >0.91 from
34% to 43% (≥0.86 from 60% to 74%) and decreased persistently
ischemic lesions (≤0.81) from 21% to 9%. Of note, however, only
74/118 (63%) of those with initial post-PCI FFR ≤0.81 actually had
further intervention attempted. In a cohort of 13 patients who fulfilled
both functional and OCT-defined criteria for suboptimal stent results,
Wolfrum et al increased the mean post-PCI FFR in this group from
0.80 ± 0.02 to 0.88 ± 0.01 through a combination of additional stent
postdilation (46%), additional stenting (39%) or a combination of both
strategies (15%). Larger increases in FFR value were observed in the
seven patients who received additional stents.45
The proposed target for an “optimal” post-PCI FFR result stems
from a meta-analysis which included several early studies that assessed
post-PCI FFR using relatively small bolus doses of intracoronary adeno-
sine to induce hyperemia. Smaller doses of adenosine may not have
achieved maximal hyperemia and could potentially have overestimated
the final FFR results. As such, a post-PCI FFR value of ≥0.90 may not
be realistic target, particularly in the left anterior descending artery
which typically subtends a larger myocardial mass. It has in fact been
suggested that optimal cutoff values of post-PCI FFR are different
according to the target vessels involved.46 Consequently, the PIOS
intervention may not be effective at increasing the FFR value to such
an extent, or at least, not in the proportions desired.
4.1 | Limitations
There are potential concerns regarding both performance and confir-
mation bias with this trial design and as such the following steps were
taken to minimize their effects.
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By its very nature, the PIOS group potentially receives more
focused attention from the interventionalist than the control group.
Despite the operator's best efforts, this does not necessarily translate
into higher final FFR values (the primary endpoint), however, and that
is the question the trial seeks to answer—does routinely applying a
post-PCI physiology-guided optimization strategy actually achieve a
clinically meaningful difference in the proportion of patients with opti-
mal final FFR results?
Following PCI procedures, the treating interventionalists
reassured all patients that they received the highest standard of care,
regardless of their randomization group. Specific results of the final
physiology measurements were not disclosed to patients in either
group.
In an effort to mitigate the potential Hawthorne (“observer”)
effect, the study could have on local PCI practices, other than cases
randomized to the PIOS intervention where post-PCI FFR was
<0.90, operators were blinded to all post-PCI physiology results,
15 different interventional cardiologists were enlisted to participate
in the trial in order to: (a) assess a wider variety of practice and
(b) dilute the exposure any one physician had to unblinded post-PCI
physiology results (on average each operator would have performed
less than 10 unblinded PIOS cases over a 20-month period). Further
details on blinding procedures are contained in the Supplementary
Appendix.
Furthermore, we posit that rather than being subject to confirma-
tion bias, the primary results of the trial will actually challenge such
bias regarding the functional results of PCI procedures.
5 | SUMMARY
TARGET FFR is an investigator-initiated, prospective, single-center,
randomized controlled trial to determine the feasibility and efficacy of
using a coronary physiology-guided optimization strategy to achieve
final post-PCI FFR results ≥0.90.
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